NYSE:HUM

Humana Inc (HUM)

409.80
+9.07 (2.26%)
as of Sep 11, 2026, 8:00:00 pm Market Open.
30 watching
0
Investor Insights
star iconSep 13, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Humana Inc (HUM-N) is characterized as a defensive name, largely owing to favorable regulatory changes, such as the lifting of Medicare premiums by former President Trump. However, despite its reputation as a solid company, Humana has exhibited significant volatility, particularly evident in its performance last January, where it plummeted by 23.8%. Analysts express concern about the company's heavy reliance on Medicare, especially with recent announcements indicating flat payment increases to healthcare providers, a stark contrast to the anticipated 5% rise. This unfavorable shift has left Humana vulnerable in the healthcare market, leading to apprehension about its future growth prospects.

consensus icon
Consensus
negative
valuation icon
Valuation
overvalued
review icon
Similar
Aetna, AET
PAST TOP PICK
(A Top Pick Sep 03/19, Up 45%) He bought it 18 months ago, when there were worries about Democratic candidates who may pressure U.S. medical insurance. The Medicare advantage is a serious tailwind given aging demographics in coming years--a lot of people will buy this insurance and Humana sits in the sweet spot. There'll be volatility in this space before the November vote, but medical insurance will remain a force. He sold some shares, but still likes this stock and sees a good long term.
TOP PICK
It is in a very interesting part of the insurance space in the US, focusing on Medicare. 10,000 people a day in the US are turning 65. The demographic tailwind is going to be huge. This is part of the healthcare market he really likes. (Analysts’ price target is $327.14)
TOP PICK
There's great opportunity in U.S. health insurers. But Pressure from politicians ahead of the 2020 election are pressuring drug and health stocks. He doesn't believe the State will go to nationalized healthcare, as the Democrats want. Humana is a Medicare Advantage provider; over 70% of revenue comes from here, and Americans are aging--demographics favour Humana. (Analysts’ price target is $334.86)
BUY ON WEAKNESS

Closed at $182.52 and his model price is only $129, so it is trading 30% over what it should be valued at. He would be interested in this at $156.

TOP PICK
Likes the Health Management Sector.
Showing 16 to 20 of 20 entries